Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in two upcoming investor conferences. On August 13, 2024, at 3:00 pm Eastern Time, CEO Brian Strem will present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. Additionally, on August 15, 2024, Strem will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.

Both presentations will be available via live webcast, with registration links provided. Replays of the presentations will be accessible on-demand for 90 days on Kiora's investor relations homepage (ir.kiorapharma.com). These conferences offer investors an opportunity to gain insights into Kiora's latest developments and future prospects.

Encinitas, California--(Newsfile Corp. - August 6, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming conferences that will be available to investors by live webcast.

On Tuesday August 13th, 2024 at 3:00 pm Eastern Time, Kiora's President and CEO, Brian Strem, Ph.D., will participate at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The presentation will be available live from this registration link and the replay will be available on-demand for 90 days on our IR homepage (ir.kiorapharma.com).

On Thursday August 15th, 2024, Kiora's President and CEO, Brian Strem, Ph.D., will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The webcast will be available live from this registration link and the replay will be available on-demand for 90 days on our IR homepage (ir.kiorapharma.com).

About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

In addition to news releases and SEC filings, we expect to post information on our website (www.kiorapharma.com) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Contacts:

Investors
investors@kiorapharma.com

Media
kiora@crowepr.com
Crowe PR

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218902

FAQ

When is Kiora Pharmaceuticals (KPRX) presenting at the Canaccord Genuity Conference?

Kiora Pharmaceuticals (KPRX) will present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, at 3:00 pm Eastern Time.

Which conferences will Kiora Pharmaceuticals (KPRX) participate in during August 2024?

Kiora Pharmaceuticals (KPRX) will participate in the Canaccord Genuity 44th Annual Growth Conference on August 13 and the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024.

How can investors access Kiora Pharmaceuticals' (KPRX) conference presentations?

Investors can access Kiora Pharmaceuticals' (KPRX) conference presentations via live webcasts. Registration links are provided, and replays will be available on-demand for 90 days on the company's investor relations homepage.

Who will be presenting on behalf of Kiora Pharmaceuticals (KPRX) at the upcoming conferences?

Brian Strem, Ph.D., President and CEO of Kiora Pharmaceuticals (KPRX), will be presenting at both upcoming investor conferences in August 2024.